Prospective phase II study of stereotactic body radiation therapy using helical tomotherapy for stage IA non-small cell lung cancer.

Prospective phase II study of stereotactic body radiation therapy using helical tomotherapy for stage IA non-small cell lung cancer. - SBRT with helical tomotherapy for lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001721

Enrollment

Registered

2009-02-20

Start date

2009-02-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stage IA non-small cell lung cancer

Interventions

patient number 50, accrual 4 years, follow-up 3years stereotactic body radiation therapy 60Gy/6fraction/8-12 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: histologically confirmed stage IA no mediastinal lymph node metastasis no previously radiotherapy history Performance status 0-2 medically unresectable or refuse of surgery written, informed consent

Exclusion criteria

Exclusion criteria: interstitial pneumonitis, lung fibrosis active infection active multiple cancer (last 3 years) pregnancy or breast feeding psychological disorder systemic steroid medication

Design outcomes

Primary

Measure	Time frame
3-year overall survival rate	—

Secondary

Measure	Time frame
overall survival time, relapse-free survival time, local pregression-free survival time, 3-year local progression free rate, type of recurrence, acute adverse event, late adverse event, ratio of severe adverse event	—

Countries

Japan

Contacts

Public ContactNatsuo Tomita

Aichi Cancer Center Hospital Department of Therapeutic Radiation Oncology

ntomita@aichi-cc.jp052-762-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026